Key Takeaways
- • Bessemer Venture Partners leads $31 million Series B funding round for Sukino Continuum Care, India's first comprehensive out-of-hospital continuum care provider, addressing a critical gap in post-acute rehabilitation services.
- • Sukino operates 850+ beds across 11 centers with 64% year-on-year growth and is currently profitable at the group level, demonstrating strong operational execution and market traction in India's underserved rehabilitation sector.
- • India's acute disease burden is substantial—accounting for approximately 10% of global stroke cases annually—with patients typically requiring six to eight weeks of multimodal rehabilitation (physical, speech, occupational, and psychological therapy) that hospital systems have inadequate incentives to provide.
- • Market tailwinds include expanding insurance coverage extending to 60–90 days of structured recovery services, addressing a previous structural gap where hospital-based rehabilitation remained financially inaccessible to most patients due to high daily costs and limited coverage.
- • The funding will support Sukino's expansion into a market where major hospital systems deprioritize longer-stay rehabilitation patients due to revenue optimization pressures, allowing Sukino to serve stroke, cancer, and orthopedic patients requiring extended care.
Summary
Bessemer Venture Partners has led a $31 million Series B funding round for Sukino Continuum Care, positioning the company to scale India's first comprehensive out-of-hospital continuum care platform. The investment reflects growing institutional recognition of a critical structural inefficiency in India's healthcare system: major hospitals are optimizing for shorter patient stays and higher revenues, systematically deprioritizing patients requiring extended rehabilitation.
India faces substantial epidemiological pressure. The country accounts for approximately 10% of global stroke cases annually—a figure rising steadily due to obesity, sedentary habits, hypertension, stress, and air pollution. Typical post-acute patients require six to eight weeks of multimodal rehabilitative care encompassing physical, speech, occupational, and psychological therapy. However, hospital-based rehabilitation remains largely inaccessible due to prohibitively high daily costs and historically limited insurance coverage, rendering extended stays financially unviable for most patients. This misalignment between clinical need and hospital incentive structures has created a significant market opportunity.
Sukino has capitalized on this gap by providing structured, affordable out-of-hospital recovery support for patients with acute diseases, including those recovering from strokes, cancer treatment, and orthopedic procedures. The company operates 850+ beds across 11 centers and has demonstrated robust execution: it achieved 64% year-on-year growth and has reached profitability at the group level. The organization has expanded substantially from treating approximately 5,000 patients at two centers in early 2021 to serving over 35,000 patients, establishing operational viability and market validation.
Two economic and cultural tailwinds accelerate Sukino's relevance. First, insurance coverage is proliferating beyond traditional hospital-focused plans to include dedicated rehabilitation care, with many health plans now covering 60–90 days of structured recovery. This regulatory and market shift addresses the previous structural impediment to continuum care adoption. The Series B capital will support further geographic and service expansion, enabling Sukino to capture market share in a fragmented, underserved segment where hospital capacity constraints and misaligned financial incentives continue to leave acute disease patients without adequate post-discharge rehabilitative pathways.
India faces substantial epidemiological pressure. The country accounts for approximately 10% of global stroke cases annually—a figure rising steadily due to obesity, sedentary habits, hypertension, stress, and air pollution. Typical post-acute patients require six to eight weeks of multimodal rehabilitative care encompassing physical, speech, occupational, and psychological therapy. However, hospital-based rehabilitation remains largely inaccessible due to prohibitively high daily costs and historically limited insurance coverage, rendering extended stays financially unviable for most patients. This misalignment between clinical need and hospital incentive structures has created a significant market opportunity.
Sukino has capitalized on this gap by providing structured, affordable out-of-hospital recovery support for patients with acute diseases, including those recovering from strokes, cancer treatment, and orthopedic procedures. The company operates 850+ beds across 11 centers and has demonstrated robust execution: it achieved 64% year-on-year growth and has reached profitability at the group level. The organization has expanded substantially from treating approximately 5,000 patients at two centers in early 2021 to serving over 35,000 patients, establishing operational viability and market validation.
Two economic and cultural tailwinds accelerate Sukino's relevance. First, insurance coverage is proliferating beyond traditional hospital-focused plans to include dedicated rehabilitation care, with many health plans now covering 60–90 days of structured recovery. This regulatory and market shift addresses the previous structural impediment to continuum care adoption. The Series B capital will support further geographic and service expansion, enabling Sukino to capture market share in a fragmented, underserved segment where hospital capacity constraints and misaligned financial incentives continue to leave acute disease patients without adequate post-discharge rehabilitative pathways.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.